Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,735 recruiting studies in this area right now.
By phase
- Not applicable9,863
- Phase 24,487
- Phase 12,736
- Phase 1/Phase 21,695
- Phase 31,409
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,239
- Prostate Cancer660
- Cancer657
- Colorectal Cancer499
- Lung Cancer431
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer302
- Pancreatic Cancer295
- Acute Myeloid Leukemia290
- Hepatocellular Carcinoma285
- Solid Tumor256
- Advanced Solid Tumor254
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer207
- Advanced Solid Tumors197
- Esophageal Cancer196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University320
- National Cancer Institute (NCI)291
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center146
- AstraZeneca131
- University Health Network, Toronto125
Where studies are running
- California1,432
- Texas644
- Arizona513
- Florida437
- Alabama418
- New York410
- Massachusetts343
- Maryland331
- New Jersey267
- Pennsylvania237
Recruiting studies20,735 total
- NCT06385080RecruitingPhase 1/Phase 2
Study of amivantamab for head and neck cancer
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT05581121RecruitingPhase 3
Lymph node removal plus standard treatment for cervical cancer
This Phase 3 trial tests whether removing specific lymph nodes in the lower pelvis and around the aorta, along with standard curative treatment, improves outcomes for people with locally advanced cervical cancer. It is mainly aimed at patients whose scans show pelvic lymph nodes involved but not clearly cancer in the para-aortic nodes.
OstravaAges 18 years+ - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT07645222RecruitingPhase 1
Testing HS-20122 combined therapy for advanced lung cancer
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT06490159Recruiting
Predicting nerve damage from paclitaxel for stomach cancer
This study looks at whether a common chemotherapy drug called paclitaxel (Taxol) causes nerve damage (peripheral neuropathy) in people with advanced stomach cancer. The goal is to find out who is most likely to get this side effect, so doctors can better protect patients during treatment.
Kurashiki, Okayama-kenAges 20 years+ - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT07085325Recruiting
Long-term follow-up study for medulloblastoma survivors treated with radiation
This study looks at the long-term health of people who were treated for medulloblastoma with craniospinal radiation at St. Jude Children's Research Hospital. It aims to understand how they are doing years after treatment.
Memphis, TennesseeAges Any age - NCT07687875RecruitingPhase 1
Virus therapy plus immunotherapy before surgery for rectal cancer
This trial tests a combination of a cancer-killing virus (oncolytic virotherapy) and an immunotherapy drug (pembrolizumab) given before surgery for a certain type of rectal cancer. It aims to see if this approach helps shrink the tumor and improve outcomes for patients whose tumors have a normal DNA repair system (pMMR).
Copenhagen, Captial RegionAges 18 years+ - NCT06314958Recruiting
Follow-up after colorectal cancer treatment
This study follows people who have finished treatment for stage II (high-risk) or stage III colorectal cancer and are now cancer-free. Researchers want to learn more about which factors might predict if the cancer will come back, so they can better personalize follow-up care.
Monrovia, CaliforniaAges 18 years+ - NCT05424029Recruiting
Test blood and lung fluid markers to predict lung cancer return
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
Basking Ridge, New JerseyAges 18 years+ - NCT07460765RecruitingPhase 1
Nivolumab with a special dye for head and neck cancer surgery
This trial tests if a special dye attached to the drug nivolumab can help surgeons see cancer cells more clearly during surgery. If you have head and neck cancer and are scheduled for surgery, this study might be an option for you.
Nashville, TennesseeAges 18 years+ - NCT06192979Recruiting
First-line treatment for AL amyloidosis with t(11;14)
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
Beijing, Beijing MunicipalityAges Any age - NCT07149207RecruitingPhase 2
Using a dye during head and neck cancer surgery
This study tests whether a special dye (ICG) injected before surgery can help surgeons see head and neck cancer more clearly during the operation. It is for people with squamous cell carcinoma who are at risk of their cancer returning and are scheduled for surgery.
Charleston, South CarolinaAges 18 years+ - NCT07684131Recruiting
Observational study of Philadelphia-positive ALL treatments
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
AmiensAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06249191RecruitingPhase 1/Phase 2
Mosunetuzumab plus chemo for untreated high-grade B-cell lymphoma
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Portland, OregonAges 18–75 - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06926283RecruitingPhase 1
Study of DXC008 for advanced prostate and other solid tumors
This trial tests a new drug called DXC008 for people with advanced solid tumors, including prostate cancer, that have not responded to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Changsha, HunanAges 18–75 - NCT06183437RecruitingPhase 4
Can I stop heart meds after cancer therapy?
This trial tests whether it is safe to stop taking heart failure medications in people who developed heart weakness after cancer treatment but whose heart function has since recovered. It aims to see if stopping these drugs leads to any worsening of heart health.
Los Angeles, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,735 recruiting oncology studies from the U.S. registry right now, out of 32,316 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.